Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Non-Current Assets for 10 consecutive years, with $3.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Assets rose 10.58% to $3.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $3.6 million, a 10.58% increase, with the full-year FY2024 number at $3.8 million, down 16.16% from a year prior.
  • Other Non-Current Assets was $3.6 million for Q2 2025 at Intellia Therapeutics, down from $3.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.2 million in Q3 2021 to a low of $3.2 million in Q2 2024.
  • A 4-year average of $4.3 million and a median of $4.5 million in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 77.22% in 2021, then decreased 16.16% in 2024.
  • Intellia Therapeutics' Other Non-Current Assets stood at $5.2 million in 2021, then dropped by 12.53% to $4.5 million in 2023, then fell by 16.16% to $3.8 million in 2024, then dropped by 6.2% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Other Non-Current Assets are $3.6 million (Q2 2025), $3.8 million (Q4 2024), and $3.2 million (Q2 2024).